FAKDX
Price
$11.95
Change
-$0.00 (-0.00%)
Updated
Sep 6 closing price
VIVIX
Price
$65.30
Change
-$0.00 (-0.00%)
Updated
Sep 6 closing price
Ad is loading...

FAKDX vs VIVIX

Header iconFAKDX vs VIVIX Comparison
Open Charts FAKDX vs VIVIXBanner chart's image
Kempner Multi-Cap Deep Value Investor
Price$11.95
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index I
Price$65.30
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FAKDX vs VIVIX Comparison Chart
Loading...
VS
FAKDX vs. VIVIX commentary
Sep 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FAKDX is a StrongBuy and VIVIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VIVIX has more cash in the bank: 183B vs. FAKDX (93.3M). VIVIX pays higher dividends than FAKDX: VIVIX (2.37) vs FAKDX (1.82). FAKDX was incepted earlier than VIVIX: FAKDX (16 years) vs VIVIX (26 years). FAKDX is a more actively managed with annual turnover of: 34.00 vs. VIVIX (10.00). FAKDX has a lower initial minimum investment than VIVIX: FAKDX (500) vs VIVIX (5000000). VIVIX (18.67) and FAKDX (18.52) have marching annual gain over last year. VIVIX return over 5 years is better than : 52.57 vs. FAKDX (21.60).
FAKDXVIVIXFAKDX / VIVIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years26 years-
Gain YTD14.95314.742101%
Front LoadN/AN/A-
Min. Initial Investment50050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets93.3M183B0%
Annual Yield % from dividends1.822.3777%
Returns for 1 year18.5218.6799%
Returns for 3 years4.2624.2618%
Returns for 5 years21.6052.5741%
Returns for 10 years21.99109.5720%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RUSHA50.892.25
+4.63%
Rush Enterprises
ON71.722.39
+3.45%
ON Semiconductor Corp
AUTL4.080.13
+3.29%
Autolus Therapeutics plc
VYNE1.840.05
+2.79%
VYNE Therapeutics
SBT5.750.04
+0.70%
Sterling Bancorp